Michael W. Fried, Maria Buti, Gregory J. Dore, Robert Flisiak, Peter Ferenci, Ira Jacobson, Patrick Marcellin, Michael Manns, Igor Nikitin, Fred Poordad, Morris Sherman, Stefan Zeuzem, Jane Scott, Leen Gilles, Oliver Lenz, Monika Peeters, Vanitha Sekar, Goedele Smedt, Maria Beumont‐Mauviel – 2 August 2013 – The phase IIb, double‐blind, placebo‐controlled PILLAR trial investigated the efficacy and safety of two different simeprevir (SMV) doses administered once‐daily (QD) with pegylated interferon (Peg‐IFN)‐α‐2a and ribavirin (RBV) in treatment‐naïve patients with HCV genotype 1 infection.

Michael W. Fried, Maria Buti, Gregory J. Dore, Robert Flisiak, Peter Ferenci, Ira Jacobson, Patrick Marcellin, Michael Manns, Igor Nikitin, Fred Poordad, Morris Sherman, Stefan Zeuzem, Jane Scott, Leen Gilles, Oliver Lenz, Monika Peeters, Vanitha Sekar, Goedele Smedt, Maria Beumont‐Mauviel – 2 August 2013 – The phase IIb, double‐blind, placebo‐controlled PILLAR trial investigated the efficacy and safety of two different simeprevir (SMV) doses administered once‐daily (QD) with pegylated interferon (Peg‐IFN)‐α‐2a and ribavirin (RBV) in treatment‐naïve patients with HCV genotype 1 infection.

Wei‐Tien Tai, Chung‐Wai Shiau, Pei‐Jer Chen, Pei‐Yi Chu, Hsiang‐Po Huang, Chun‐Yu Liu, Jui‐Wen Huang, Kuen‐Feng Chen – 2 August 2013 – Sorafenib is the first approved targeted therapeutic reagent for hepatocellular carcinoma (HCC). Here, we report that Src homology region 2 (SH2) domain‐containing phosphatase 1 (SHP‐1) is a major target of sorafenib and generates a series of sorafenib derivatives to search for potent SHP‐1 agonists that may act as better anti‐HCC agents than sorafenib.

Nicola Santoro, Sonia Caprio – 2 August 2013

Cynthia A. Moylan, Herbert Pang, Andrew Dellinger, Ayako Suzuki, Melanie E. Garrett, Cynthia D. Guy, Susan K. Murphy, Allison E. Ashley‐Koch, Steve S. Choi, Gregory A. Michelotti, Daniel D. Hampton, Yuping Chen, Hans L. Tillmann, Michael A. Hauser, Manal F. Abdelmalek, Anna Mae Diehl – 2 August 2013 – Clinicians rely upon the severity of liver fibrosis to segregate patients with well‐compensated nonalcoholic fatty liver disease (NAFLD) into subpopulations at high‐ versus low‐risk for eventual liver‐related morbidity and mortality.

Nathalie Sela, Kris P. Croome, Natasha Chandok, Paul Marotta, William Wall, Roberto Hernandez‐Alejandro – 2 August 2013 – Liver donor characteristics have a significant impact on graft quality and, in turn, recipient outcomes. In this study, we examined deceased liver donor characteristics and donor risk index (DRI) trends in Canada over the past decade. Data were extracted from the Canadian Organ Replacement Register and Transplant Québec for the decade (2000‐2010).

Geoffrey W. McCaughan, David G. Bowen, Patrick Bertolino – 2 August 2013

David N. Assis, Lin Leng, Xin Du, Clarence K. Zhang, Gerrit Grieb, Melanie Merk, Alvaro Baeza Garcia, Catherine McCrann, Julius Chapiro, Andreas Meinhardt, Yuka Mizue, David J. Nikolic‐Paterson, Jürgen Bernhagen, Marshall M. Kaplan, Hongyu Zhao, James L. Boyer, Richard Bucala – 2 August 2013 – The role of the cytokine, macrophage migration inhibitory factor (MIF), and its receptor, CD74, was assessed in autoimmune hepatitis (AIH) and primary biliary cirrhosis (PBC).

Lionel Lim, Asha Balakrishnan, Noelle Huskey, Kirk D. Jones, Mona Jodari, Raymond Ng, Guisheng Song, Jesse Riordan, Brittany Anderton, Siu‐Tim Cheung, Holger Willenbring, Adam Dupuy, Xin Chen, David Brown, Aaron N. Chang, Andrei Goga – 2 August 2013 – Hepatocellular carcinoma (HCC) is associated with poor survival for patients and few effective treatment options, raising the need for novel therapeutic strategies. MicroRNAs (miRNAs) play important roles in tumor development and show deregulated patterns of expression in HCC.

Santseharay Ramirez, Yi‐Ping Li, Sanne B. Jensen, Jannie Pedersen, Judith M. Gottwein, Jens Bukh – 2 August 2013 – Hepatitis C virus (HCV) is a genetically diverse virus with multiple genotypes exhibiting remarkable differences, particularly in drug susceptibility. Drug and vaccine development will benefit from high‐titer HCV cultures mimicking the complete viral life cycle, but such systems only exist for genotypes 1a and 2a. We developed efficient culture systems for the epidemiologically important genotype 2b.